Abstract
Prevention of hepatitis is a worldwide issue. For most patients with liver disease, hepatoprotective drugs are required. But there are only a few hepatoprotective drugs available. Osthole is a coumarin compound and protects the liver from hepatitis by preventing the development of apoptosis. However, osthole exhibits low water solubility, and some structural modifications are required for sufficient hepatoprotection upon oral administration. We synthesized 28 osthole derivatives, and then studied their effects by using mice concanavalin A (Con A) -induced hepatitis. The osthole derivatives No.1, 9 and 19 showed stronger inhibition of Con A-induced elevation of plasma alanine aminotransferase (ALT). Oral administration of osthole at the dose of 100 mg/kg (n=10) inhibited 38.0 % of the Con A-induced elevation of plasma ALT. In contrast, oral administration of Nos. 1, 9 and 19 at the dose of 100 mg/kg (n=5) caused 68.7%, 62.5% and 88.3% inhibition of the Con A-induced elevation of plasma ALT, respectively. These synthetic osthole derivatives could contribute to the development of hepatoprotective drugs effective for various types of liver diseases on oral administration.
Keywords: Osthole Skeleton, nitrocoumarin, allyloxycoumarin, nitroquinoline, Apoptosis
Medicinal Chemistry
Title: Synthetic Derivatives of Osthole for the Prevention of Hepatitis
Volume: 3 Issue: 1
Author(s): Toshihiro Okamoto, Tadashi Kobayashi and Shinic hi Yoshida
Affiliation:
Keywords: Osthole Skeleton, nitrocoumarin, allyloxycoumarin, nitroquinoline, Apoptosis
Abstract: Prevention of hepatitis is a worldwide issue. For most patients with liver disease, hepatoprotective drugs are required. But there are only a few hepatoprotective drugs available. Osthole is a coumarin compound and protects the liver from hepatitis by preventing the development of apoptosis. However, osthole exhibits low water solubility, and some structural modifications are required for sufficient hepatoprotection upon oral administration. We synthesized 28 osthole derivatives, and then studied their effects by using mice concanavalin A (Con A) -induced hepatitis. The osthole derivatives No.1, 9 and 19 showed stronger inhibition of Con A-induced elevation of plasma alanine aminotransferase (ALT). Oral administration of osthole at the dose of 100 mg/kg (n=10) inhibited 38.0 % of the Con A-induced elevation of plasma ALT. In contrast, oral administration of Nos. 1, 9 and 19 at the dose of 100 mg/kg (n=5) caused 68.7%, 62.5% and 88.3% inhibition of the Con A-induced elevation of plasma ALT, respectively. These synthetic osthole derivatives could contribute to the development of hepatoprotective drugs effective for various types of liver diseases on oral administration.
Export Options
About this article
Cite this article as:
Okamoto Toshihiro, Kobayashi Tadashi and hi Yoshida Shinic, Synthetic Derivatives of Osthole for the Prevention of Hepatitis, Medicinal Chemistry 2007; 3 (1) . https://dx.doi.org/10.2174/157340607779317607
DOI https://dx.doi.org/10.2174/157340607779317607 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Lipid Raft Alterations in Aged-Associated Neuropathologies
Current Alzheimer Research Pathogenesis of HIV-Associated Non-Hodgkin Lymphoma
Current HIV Research Receptor for Advanced Glycation End Products (RAGE): A Novel Therapeutic Target for Diabetic Vascular Complication
Current Pharmaceutical Design The Biology of Persistent Infection: Inflammation and Demyelination Following Murine Coronavirus Infection of the Central Nervous System
Current Immunology Reviews (Discontinued) Editorial: Frontier Views in Designing Therapeutic Candidates for Management of Diverse Diseases
Current Pharmaceutical Design Role of Contrast-Enhanced Ultrasound in the Follow-up of Endo-Vascular Aortic Aneurysm Repair: an Effective and Safe Surveillance Method
Current Pharmaceutical Design The Anti-Atherogenic Effects of Thiazolidinediones
Current Diabetes Reviews Oxytocin - A Multifunctional Analgesic for Chronic Deep Tissue Pain
Current Pharmaceutical Design Preface
Current Pharmaceutical Design Targeting Adenosine Signaling to Treatment of Diabetic Nephropathy
Current Drug Targets Cardioprotective effects of Aronia melanocarpa anthocynanins. From laboratory experiments to clinical practice.
Current Pharmaceutical Design Polymorphism of UDP-Glucuronosyltransferase and Drug Metabolism
Current Drug Metabolism Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) Micro RNA: An Epigenetic Regulator of Type 2 Diabetes
MicroRNA Monoclonal Antobodies: Application in Radiopharmacy
Current Radiopharmaceuticals JLK Inhibitors: Isocoumarin Compounds as Putative Probes to Selectively Target the γ-Secretase Pathway
Current Alzheimer Research Metabolism of Direct-acting Antiviral Agents (DAAs) in Hepatitis C Therapy: A Review of the Literature
Current Drug Metabolism Febrile Infection-Related Epilepsy Syndrome (FIRES): An Overview of Treatment and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery Plant Proteomics and Peptidomics in Host-Pathogen Interactions: The Weapons Used by Each Side
Current Protein & Peptide Science Can we Succeed in the Fight Against SARS-CoV-2 with its Emerging New Variants?
Current Pharmaceutical Design